Terms: = Gastric cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
24 results:
1. Preoperative NUn score serves as a robust predictor of overall and disease-specific survivals following radical surgery for gastric cancer.
Urabe M; Okumura Y; Okamoto A; Yajima S; Yagi K; Yamashita H; Seto Y
Langenbecks Arch Surg; 2024 Apr; 409(1):126. PubMed ID: 38619630
[TBL] [Abstract] [Full Text] [Related]
2. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG; Lyu SI; Laible M; Wöll S; Türeci Ö; Şahin U; Alakus H; Fahrig L; Zander T; Buettner R; Bruns CJ; Schroeder W; Gebauer F; Quaas A
J Transl Med; 2023 Aug; 21(1):552. PubMed ID: 37592303
[TBL] [Abstract] [Full Text] [Related]
3. Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022.
Chen Y; Chen Y; Tan S; Zheng Y; Liu S; Zheng T; Mi Y; Lin S; Yang C; Li W
Hum Vaccin Immunother; 2023 Dec; 19(1):2186684. PubMed ID: 37017186
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer.
Zhang R; Hu C; Zhang J; Zhang Y; Yuan L; Yu P; Wang Y; Bao Z; Cao M; Ruan R; Cheng X; Xu Z
BMC Cancer; 2023 Jan; 23(1):5. PubMed ID: 36597055
[TBL] [Abstract] [Full Text] [Related]
5. Gastrointestinal toxicity of systemic oncology immunotherapy.
Bureš J; Kohoutová D; Zavoral M
Klin Onkol; 2022; 35(5):346-357. PubMed ID: 36443091
[TBL] [Abstract] [Full Text] [Related]
6. Advances in car T-cell therapy in bile duct, pancreatic, and gastric cancers.
Feng Q; Sun B; Xue T; Li R; Lin C; Gao Y; Sun L; Zhuo Y; Wang D
Front Immunol; 2022; 13():1025608. PubMed ID: 36341440
[TBL] [Abstract] [Full Text] [Related]
7. Single-cell RNA-Seq reveals the potential risk of anti-mesothelin car T Cell therapy toxicity to different organs in humans.
Wen L; Huang Y; Peng L; Zhao K; Sun Y; Lin Z; Chen Y; Li Z; Qian Q; Tong F; Zhang R; Dong X
Front Immunol; 2022; 13():807915. PubMed ID: 36059490
[TBL] [Abstract] [Full Text] [Related]
8. Recent Progress and Future Perspectives of Immunotherapy in Advanced gastric cancer.
Jin X; Liu Z; Yang D; Yin K; Chang X
Front Immunol; 2022; 13():948647. PubMed ID: 35844558
[TBL] [Abstract] [Full Text] [Related]
9. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract] [Full Text] [Related]
10. Neutrophil-to-lymphocyte ratio and C-reactive protein-to-albumin ratio as prognostic factors for unresectable advanced or recurrent gastric cancer.
Namikawa T; Shimizu S; Yokota K; Tanioka N; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Langenbecks Arch Surg; 2022 Mar; 407(2):609-621. PubMed ID: 34652563
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic and clinicopathological significance of C-reactive protein/albumin ratio (car) in patients with gastric cancer: A meta-analysis.
Yu J; Liu H; Zeng X; Zhao Y; Jiang D; Lu H; Qian J
PLoS One; 2021; 16(4):e0250295. PubMed ID: 33901218
[TBL] [Abstract] [Full Text] [Related]
12. cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
Walcher L; Kistenmacher AK; Suo H; Kitte R; Dluczek S; Strauß A; Blaudszun AR; Yevsa T; Fricke S; Kossatz-Boehlert U
Front Immunol; 2020; 11():1280. PubMed ID: 32849491
[TBL] [Abstract] [Full Text] [Related]
13. car T‑cell therapy for gastric cancer: Potential and perspective (Review).
Long B; Qin L; Zhang B; Li Q; Wang L; Jiang X; Ye H; Zhang G; Yu Z; Jiao Z
Int J Oncol; 2020 Apr; 56(4):889-899. PubMed ID: 32319561
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy of Neoadjuvant Chemotherapy in Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-car) for Locally Advanced Pancreatic cancer.
Yoshiya S; Fukuzawa K; Inokuchi S; Kosai-Fujimoto Y; Sanefuji K; Iwaki K; Motohiro A; Itoh S; Harada N; Ikegami T; Yoshizumi T; Mori M
J Gastrointest Surg; 2020 Jul; 24(7):1605-1611. PubMed ID: 31325134
[TBL] [Abstract] [Full Text] [Related]
15. Ischemic gastropathy after distal pancreatectomy with en bloc celiac axis resection for pancreatic body cancer.
Okada KI; Kawai M; Hirono S; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Shimokawa T; Yamaue H
Langenbecks Arch Surg; 2018 Aug; 403(5):561-571. PubMed ID: 29956031
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic Significance of the Preoperative Ratio of C-Reactive Protein to Albumin and Neutrophil-Lymphocyte Ratio in gastric cancer Patients.
Saito H; Kono Y; Murakami Y; Shishido Y; Kuroda H; Matsunaga T; Fukumoto Y; Osaki T; Ashida K; Fujiwara Y
World J Surg; 2018 Jun; 42(6):1819-1825. PubMed ID: 29270656
[TBL] [Abstract] [Full Text] [Related]
17. Clinical Burden of C-Reactive Protein/Albumin Ratio Before Curative Surgery for Patients with gastric cancer.
Toiyama Y; Shimura T; Yasuda H; Fujikawa H; Okita Y; Kobayashi M; Ohi M; Yoshiyama S; Hiro J; Araki T; Inoue Y; Mohri Y; Kusunoki M
Anticancer Res; 2016 Dec; 36(12):6491-6498. PubMed ID: 27919972
[TBL] [Abstract] [Full Text] [Related]
18. [R0 Resection by Distal Pancreatectomy with En Bloc Celiac Axis Resection after Down-Staging by FOLFIRINOX Therapy in a Case of Pancreas cancer--Report of a Case].
Makino H; Kametaka H; Fukada T; Seike K; Koyama T; Hasegawa A
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1644-6. PubMed ID: 26805124
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathological roles of aberrantly expressed recoverin in malignant tumor cells.
Matsuo S; Ohguro H; Ohguro I; Nakazawa M
Ophthalmic Res; 2010; 43(3):139-44. PubMed ID: 19887879
[TBL] [Abstract] [Full Text] [Related]
20. Clinicopathological features of gastric cancer cases and aberrantly expressed recoverin.
Ohguro H; Odagiri H; Miyagawa Y; Ohguro I; Sasaki M; Nakazawa M
Tohoku J Exp Med; 2004 Mar; 202(3):213-9. PubMed ID: 15065647
[TBL] [Abstract] [Full Text] [Related]
[Next]
